Last edition
News about " AI-driven drug discovery"
AbbVie and Iambic Partner on AI-Driven Drug Discovery
AbbVie and Iambic partner to accelerate Artificial Intelligence (AI)-driven small molecule drug discovery across immunology, neuroscience and oncology.
AI-driven Drug Discovery | 22/09/2026 | By News Bureau | 118
The drug discovery services market is projected to reach USD 39.79 billion by 2030, driven by Artificial Intelligence (AI) adoption, outsourcing, biologics, precision medicine and regional sourcing.
AI-driven Drug Discovery | 16/09/2026 | By News Bureau | 128
Novo Nordisk and AWS Partner to Accelerate AI-Driven Drug Discovery
Novo Nordisk and AWS are partnering to accelerate AI-driven drug discovery, with a new London AI hub and AWS becoming Novo Nordisk’s preferred cloud provider.
AI-driven Drug Discovery | 12/08/2026 | By News Bureau | 133
The collaboration between Insilico Medicine and Bora Pharmaceuticals is valued at over USD 2.5 billion if fully implemented and aims to accelerate the discovery, development and commercialisation of next-generation therapies while expanding AI adoption across the pharmaceutical value chain.
AI Driven Drug Discovery | 16/07/2026 | By News Bureau | 153
Evogene and Tel Aviv University Launch AI Drug Discovery Initiative
Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery have launched a joint initiative combining Artificial Intelligence (AI)-driven computational chemistry with advanced experimental capabilities to accelerate small-molecule drug discovery.
AI-driven Drug Discovery | 08/07/2026 | By News Bureau | 156
Insilico Medicine and SK Biopharmaceuticals have entered an Artificial Intelligence (AI)-powered drug discovery collaboration worth up to USD 2.5 billion to develop innovative therapies for neuroimmune disorders.
AI-driven Drug Discovery | 23/06/2026 | By News Bureau | 477
Insilico Begins Phase 1 Trial of AI-Designed NLRP3 Inhibitor ISM8969
Insilico Medicine has completed first-in-human dosing of its AI-designed NLRP3 inhibitor ISM8969 in a phase 1 clinical trial. The oral, brain-penetrant therapy is being developed with Hygtia Therapeutics for chronic neuroinflammation and CNS disorders, including Parkinson’s disease, marking a key milestone in AI-driven drug development.
AI-driven Drug Discovery | 18/06/2026 | By News Bureau | 152
Evotec SE and Almirall S.A. Advance Dermatology Drug Candidate to Preclinical Stage
The Evotec–Almirall collaboration showcases the power of AI-driven drug discovery, rapidly advancing a promising dermatology candidate toward clinical development for unmet medical needs.
AI-driven Drug Discovery | 05/05/2026 | By News Bureau | 133
TaiGen Biotechnology doses first participant in Phase I trial of ISM4808, an AI-designed oral therapy from Insilico Medicine for chronic kidney disease-related anemia.
AI Driven Drug Discovery | 09/03/2026 | By News Bureau | 316
Illumina Launches Billion Cell Atlas to Power AI-Driven Drug Discovery
Illumina, Inc. has launched the Illumina Billion Cell Atlas, the world’s largest genome-wide genetic perturbation dataset, designed to accelerate AI-enabled drug discovery across the pharmaceutical industry.
AI-Driven Drug Discovery | 15/01/2026 | By Darshana | 323
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy